BERLIN -- A single infusion of the investigational PRAME-directed T-cell receptor T-cell therapy anzutresgene autoleucel (anzu-cel) showed encouraging antitumor activity in patients with previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback